Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer
- Lili Huang
- Chuanqi Qin
- Li Wang
- Tiejun Zhang
- Jianguo Li
Affiliations: Department of Intensive Care Unit, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Anesthesiology, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China
- Published online on: December 10, 2020 https://doi.org/10.3892/ol.2020.12367
Copyright: © Huang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Oral cancer is one of the most common malignancies in the world. The present study aimed to investigate the effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer. Patients were randomly divided into the dexmedetomidine and control groups. Within 15 min before anesthesia induction, dexmedetomidine was infused with a 0.5 µg·kg‑1 loading dose followed by a maintenance dose of 0.4 µg·kg‑1·h‑1 to the end of operation in the dexmedetomidine group, whereas the same volume of saline was administered in the control group. Blood samples were obtained at five time‑points: 30 min Before induction (T0), 1 h after induction (T1), end of the operation (T2) and 24 (T3) and 48 h (T4) after the operation. The T lymphocyte subsets (including CD3+, CD4+ and CD8+ cells) and CD4+/CD8+ ratio, B lymphocytes, dendritic cells and myeloid‑derived suppressor cells (MDSCs) were analyzed by flow cytometry. All immunological indicators, except CD8+ cells, significantly decreased between the two groups at T1‑3 compared with T0 (P<0.05). The percentages of CD3+, CD4+, dendritic cells and the CD4+/CD8+ ratios were significantly higher at T2‑4 and the percentages of MDSCs were significantly lower at T2‑4 in the dexmedetomidine group compared with the control group (all P<0.05). These findings suggested that dexmedetomidine can attenuate immunosuppression in patients undergoing radical and reconstructive surgery for oral cancer.